The cell lines carrying the KRAS.G12X oncogenic mutations all showed an increase in the rate of cell proliferation compared to the KRAS.G12G (WT) control cell line, demonstrating that one copy of the endogenous KRAS.G12X oncogenic mutation is sufficient to induce this cancer relevant phenotype in hTERT RPE-1 cells. This evidence concerns the gene KRAS and cancer.